Patient | Age | FIGO | Tumor size (mm)* | n LN +of total LN | p16† | HPV-typing | Collected tissue after SLN procedure | Collected tissue after lymphadenectomy | Metastasis size (mm)* | |||
SLN− (n=21) | Non-SLN− (n=4) | SLN+ (n=3) | LN− (n=2) | LN+ (n=8) | ||||||||
1 | 38 | IB | 0 | 0/6 | Neg | n/a | 2 | 1 | – | – | – | – |
2 | 56 | IB | 24 | 0/3 | Neg | n/a | 1 | 1 | – | – | – | – |
3 | 49 | IIIB | 32 | 2/13 | Neg | n/a | 1 | 1 | 1 | – | – | 2 |
4 | 68 | IB | 0 | 0/3 | Neg | n/a | 3 | – | – | – | – | – |
5 | 45 | IB | 0 | 0/6 | Neg | n/a | 2 | – | – | – | – | – |
6 | 50 | IB | 9 | 0/7 | Neg | n/a | 1 | – | – | – | – | – |
7 | 40 | IB | 0 | 0/3 | Pos | n/a | 2 | – | – | – | – | – |
8‡‡ | 48 | IB | 5 | 0/4 | n/a | HPV16 | 1 | – | – | – | – | – |
9 | 52 | IIIB | 35 | 4/18 | Pos | n/a | – | – | – | 1 | 1 | 35 |
10 | 72 | IIIB | 15 | 3/15 | n/a | HPV16 | – | – | – | 1 | 1 | n/a (macro) |
11 | 58 | IIIC | 40 | 2/9 | Pos | n/a | – | – | – | – | 1 | 15 |
12 | 74 | IIIB | 40 | 3/18 | Neg | n/a | – | – | – | – | 1 | 19 |
13 | 71 | IB | 28 | 0/10 | Pos | n/a | 1 | 1 | – | – | – | – |
14 | 89 | IIIA | 29 | 2/11 | Pos | n/a | – | – | – | – | 1 | 13 |
15 | 72 | IB | 24 | 0/2 | Neg | n/a | 1 | – | – | – | – | – |
16 | 64 | IB | 9 | 0/3 | Pos | n/a | 1 | – | – | – | – | – |
17 | 89 | IB | 21 | 0/4 | Neg | n/a | 1 | – | – | – | – | – |
18 | 58 | IB | 1.5 | 0/2 | Pos | n/a | 1 | – | – | – | – | – |
19 | 51 | IB | 24 | 0/6 | n/a | HPV16 | 1 | – | – | – | – | – |
20 | 56 | IIIA | 30 | 1/7 | Pos | n/a | – | – | 1 | – | – | 3 |
21 | 75 | IIIA | 70 | 1/8 | Neg | n/a | – | – | – | – | 1 | 45 |
22 | 63 | IB | 29 | 0/6 | Pos | n/a | 1 | – | – | – | – | – |
23 | 74 | II | 40¶ | 0/7 | Pos | n/a | 1 | – | – | – | – | – |
24 | 66 | IIIA | 40¶ | 1/9 | Neg | n/a | – | – | 1 | – | – | 0.18 |
25§ | 77 | IIIC | 60 | 17/18 | Pos | n/a | – | – | – | – | 2 | 30 |
*(Metastatic) tumor size based on pathology review after vulvectomy, some tumors (0 mm) were already fully resected before SLN procure.
†Immunohistochemistry for p16 performed on archived primary tumor material.
‡Patient participated in HPV DNA-vaccination trial 15 months before surgery (Dutch trial no. NL4474).
§Patient received en bloc vulvectomy and lymphadenectomy, but had recurrent disease already after 1 month.s.
¶Tumor size based on clinical examination.
FIGO, International Federation of Gynecology and Obstetrics; HPV, human papillomaviruses; LN−, tumor-negative lymph node; LN+, tumor-positive lymph node; n/a, not available; non-SLN−, tumor-negative non-sentinel lymph node; SLN−, tumor-negative sentinel lymph node.